On October 19, 2026, President Trump signed an executive order titled "Advancing Women's Health to Improve Outcomes in All Phases of Life" creating a dedicated Women's Health Division within the National Institutes of Health (NIH) and establishing a White House Women's Health Task Force. The division must be established within 90 days and will coordinate with the existing Office of Research on Women's Health to advance research into understudied conditions affecting women including cardiovascular disease, cancer, Alzheimer's disease, endometriosis, fibroids, infertility, maternal health, and menopause. The task force will be co-chaired by White House Chief of Staff Susie Wiles and Health and Human Services Secretary Robert F. Kennedy Jr. The order does not include specific funding allocations but directs HHS to cover administrative costs of the task force. The executive order revokes Biden's March 2024 executive order on women's health research and a November 2023 White House memorandum on women's health initiatives.
Women's health research has historically received less federal investment and attention compared to health conditions affecting men. The Office of Research on Women's Health was established in 1990 but remained modest in scope. President Biden signed an executive order in March 2024 prioritizing women's health research investments and directing federal agencies to report annually on women's health spending. The Trump administration's approach reverses Biden-era policies while creating new structures ostensibly focused on women's health research, although it occurs amid broader Trump administration proposals for significant cuts to NIH funding, including requests to cut 12-40 percent of the NIH budget in recent fiscal years.
Verified Facts
Executive order signed October 19, 2026, titled 'Advancing Women's Health to Improve Outcomes in All Phases of Life'
Order directs HHS, through NIH director, to establish Women's Health Division within 90 days
New division will coordinate with existing Office of Research on Women's Health (established 1990)
White House Women's Health Task Force co-chaired by Susie Wiles and Robert F. Kennedy Jr.
HHS will pay administrative costs of task force; no specific funding allocations disclosed for division
Order revokes Biden's March 2024 executive order on women's health research and November 2023 White House memorandum
Women's health organizations including SWHR, ACOG, and WFRC issued joint statement welcoming the order
Division will focus on cardiovascular disease, cancer, Alzheimer's, endometriosis, fibroids, infertility, maternal health, menopause, and polyendocrine metabolic ovary syndrome
Participants
All participant attributions are sourced
DTDonald Trump45th & 47th President of the United StatesDecided
MTMelania TrumpAgreed
Perspectives
Left
Critics note the order occurs amid Trump administration proposals for major NIH budget cuts and comes after the administration terminated funding for the Women's Health Initiative, a longstanding NIH program, raising questions about genuine commitment to women's health research.
Trump Administration Creates Women's Health Research Division and Task Force Amid Broader Healthcare Funding Cuts
The executive order was signed amid broader Trump administration efforts to cut federal healthcare spending, including a fiscal 2027 budget proposal requesting a 12 percent reduction in NIH funding and earlier proposals for cuts as high as 40 percent. Critics note the administration terminated funding for the Women's Health Initiative, a major NIH program running for over three decades with 42,000 participants, in April 2025. While the administration also removed safety warnings from hormone replacement therapy products and urged expanded study of testosterone therapies for women, the context of overall healthcare funding reductions and elimination of established women's health programs raises questions about the order's practical impact. First Lady Melania Trump championed the initiative, with the order framed as addressing a gap that previous administrations had not filled.
Key takeaway
Critics should monitor whether the new Women's Health Division receives adequate resources or remains symbolic given concurrent NIH budget cut proposals and termination of established women's health programs.
Right
Supporters praise the executive order as creating overdue structural focus on women's health research and establishing coordinated federal leadership to translate research into clinical practice and improve outcomes across all life stages.
Trump Launches Major Women's Health Initiative: New NIH Division and White House Task Force to Advance Research
The executive order represents a significant recognition of women's health as a federal priority, establishing dedicated structural resources for women-focused health research that did not previously exist as a standalone division within NIH. The task force and division will coordinate research into major health challenges uniquely or disproportionately affecting women, including cardiovascular disease (the leading cause of death among women), cancer, Alzheimer's disease, reproductive health conditions, and mental health. By consolidating women's health research under a dedicated division and establishing high-level White House coordination through the task force co-chaired by the Chief of Staff and HHS Secretary, the order aims to accelerate translation of research findings into clinical practice and policy. First Lady Melania Trump's advocacy for the initiative underscores administration commitment to modernizing women's healthcare across all life stages.
Key takeaway
The order creates long-needed structural focus on women's health within NIH and establishes high-level White House coordination to accelerate research translation into clinical practice.
Straight
Trump Signs Order Creating NIH Women’s Health Division and Task Force
President Trump signed an executive order on October 19, 2026, creating a new Women's Health Division at the National Institutes of Health and a White House Women's Health Task Force to advance research into conditions affecting women. The order directs HHS to establish the division within 90 days and mandates coordination with the existing Office of Research on Women's Health. The task force will be led by White House Chief of Staff Susie Wiles and HHS Secretary Robert F. Kennedy Jr., with first meeting held on signing day. The order targets research into cardiovascular disease, cancer, Alzheimer's disease, endometriosis, fibroids, infertility, maternal health, menopause, and other conditions. HHS will fund administrative costs but the order does not specify funding for research. The executive order explicitly revokes Biden's March 2024 women's health research executive order and a November 2023 White House memorandum establishing a women's health initiative. Multiple women's health organizations, including the Society for Women's Health Research, American College of Obstetricians and Gynecologists, and Women First Research Coalition, welcomed the order.
Key takeaway
The order's real-world impact depends on implementation decisions regarding funding, division placement within NIH, and task force operations, which remain to be determined.
The Analysis
The executive order reflects a rhetorical pivot toward women's health as a policy priority while occurring within a broader Trump administration context of healthcare funding constraints. The 90-day establishment deadline for the division is concrete, but the lack of specific funding commitments for the division or research priorities creates ambiguity about resources. The order's explicit revocation of Biden-era women's health orders reflects partisan competition over health policy direction. The enthusiasm from major women's health organizations suggests the order's structural framework addresses genuine research coordination gaps, yet the administration's simultaneous termination of the Women's Health Initiative (involving 42,000 ongoing participants) and broader NIH budget reduction proposals create tension with expansion claims. The co-chair selection of Susie Wiles (a political operative who recently recovered from cancer) and Robert F. Kennedy Jr. (whose views on vaccine safety and pharmaceutical regulation are controversial among mainstream health scientists) signals the administration's priorities may extend beyond traditional biomedical research. Whether this order results in accelerated women's health research or primarily represents institutional restructuring remains unclear pending funding and implementation decisions.
AI-generated editorial framing, not objective fact — methodology
Consequence Chain
No consequences linked yet.
Why It Matters
Women's health research historically received disproportionately lower funding relative to disease burden, with conditions uniquely affecting women (endometriosis, fibroids, menopause, gestational diabetes) understudied. Creating a dedicated NIH division could improve coordination and research efficiency. However, the order's practical impact depends on funding decisions occurring amid contested NIH budget reductions. The order also reflects ongoing partisan disputes over women's health policy priorities, with the Biden and Trump administrations pursuing opposite approaches to women's health research and reproductive healthcare access.